Akebia Therapeutics Stock Price, News & Analysis (NASDAQ:AKBA)

$15.23 +0.20 (+1.33 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$15.23
Today's Range$14.73 - $15.26
52-Week Range$8.58 - $20.25
Volume365,142 shs
Average Volume290,441 shs
Market Capitalization$719.91 million
P/E Ratio-4.82
Dividend YieldN/A
Beta0.79

About Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AKBA
CUSIPN/A
Phone+1-617-8712098

Debt

Debt-to-Equity RatioN/A
Current Ratio2.21%
Quick Ratio2.21%

Price-To-Earnings

Trailing P/E Ratio-4.81962025316456
Forward P/E Ratio-6.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.53 million
Price / Sales470.54
Cash FlowN/A
Price / CashN/A
Book Value$1.78 per share
Price / Book8.56

Profitability

Trailing EPS($3.16)
Net Income$-135,740,000.00
Net Margins-137.80%
Return on Equity-198.85%
Return on Assets-41.16%

Miscellaneous

Employees90
Outstanding Shares47,270,000

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. The biopharmaceutical company earned $41.28 million during the quarter, compared to analysts' expectations of $34 million. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. View Akebia Therapeutics' Earnings History.

When will Akebia Therapeutics make its next earnings announcement?

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Akebia Therapeutics.

Where is Akebia Therapeutics' stock going? Where will Akebia Therapeutics' stock price be in 2018?

8 analysts have issued 1-year price objectives for Akebia Therapeutics' shares. Their forecasts range from $17.00 to $30.00. On average, they anticipate Akebia Therapeutics' stock price to reach $23.50 in the next twelve months. View Analyst Ratings for Akebia Therapeutics.

What are Wall Street analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:

  • 1. Mizuho analysts commented, "We had a chance to catch up with CEO John Butler yesterday at the Bio CEO & Investor Conference. We summarize our key takeaways below. Akebia also provided an update on the Vadadustat development program yesterday morning including an expansion of the ongoing phase 2 For2ward and phase 3 Trilo2gy trials in collaboration with Otsuka (TYO:4578, Non rated). While this will delay the timeline for topline data in both programs, we see it as a positive overall as the company will now incorporate additional relevant endpoints with a greater number of patients for better positioning in commercialization. The timeline for data-readouts in the two pivotal Pro2tect and Inno2vate trials remains unchanged." (2/13/2018)
  • 2. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (1/2/2018)
  • 3. Aegis analysts commented, "We expect totals sales for Shire’s HAE franchise to reach $1.9B by 2021. Consensus is only at $1.8B. We think Lanadelumab has peak sales potential of $2B worldwide and the entire HAE franchise has peak sales potential of $2.3B. Shire expects to launch Lanadelumab in 2H18. The product will have a 8-month review at the FDA." (6/30/2017)

Who are some of Akebia Therapeutics' key competitors?

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the folowing people:

  • Muneer A. Satter J.D., Independent Chairman of the Board (Age 56)
  • John P. Butler, President, Chief Executive Officer, Director (Age 52)
  • Jason A. Amello, Chief Financial Officer, Senior Vice President, Treasurer (Age 48)
  • Nicole R. Hadas, Senior Vice President, General Counsel, Secretary (Age 44)
  • Michel Dahan, Senior Vice President and Chief Business Officer (Age 38)
  • Rita Jain M.D., Senior Vice President, Chief Medical Officer
  • Karen Tubridy, Senior Vice President, Chief Development Officer (Age 54)
  • Scott A. Canute, Independent Director (Age 57)
  • Michael D. Clayman M.D., Independent Director (Age 65)
  • Maxine Gowen Ph.D., Independent Director (Age 59)

Who owns Akebia Therapeutics stock?

Akebia Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.26%), Eagle Asset Management Inc. (5.75%), Carillon Tower Advisers Inc. (4.36%), Perceptive Advisors LLC (4.20%), Renaissance Technologies LLC (3.85%) and Millennium Management LLC (2.17%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.

Who sold Akebia Therapeutics stock? Who is selling Akebia Therapeutics stock?

Akebia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Eagle Asset Management Inc., Acadian Asset Management LLC, Geode Capital Management LLC, Deutsche Bank AG, TIAA CREF Investment Management LLC, Adams Diversified Equity Fund Inc. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Akebia Therapeutics company stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.

Who bought Akebia Therapeutics stock? Who is buying Akebia Therapeutics stock?

Akebia Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Renaissance Technologies LLC, Perceptive Advisors LLC, Millennium Management LLC, BlackRock Inc., American Century Companies Inc., Farallon Capital Management LLC and Spark Investment Management LLC. View Insider Buying and Selling for Akebia Therapeutics.

How do I buy Akebia Therapeutics stock?

Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of Akebia Therapeutics stock can currently be purchased for approximately $15.23.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $719.91 million and generates $1.53 million in revenue each year. The biopharmaceutical company earns $-135,740,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. Akebia Therapeutics employs 90 workers across the globe.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 1st St Ste 1100, CAMBRIDGE, MA 02142-1292, United States. The biopharmaceutical company can be reached via phone at +1-617-8712098 or via email at [email protected]


MarketBeat Community Rating for Akebia Therapeutics (AKBA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  352
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akebia Therapeutics (NASDAQ:AKBA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.882.833.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.50$23.50$22.00$21.80
Price Target Upside: 62.63% upside56.15% upside54.49% upside60.06% upside

Akebia Therapeutics (NASDAQ:AKBA) Consensus Price Target History

Price Target History for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ:AKBA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018MizuhoReiterated RatingBuy$24.00LowView Rating Details
12/18/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$26.00MediumView Rating Details
12/7/2017BTIG ResearchInitiated CoverageBuy -> Buy$30.00MediumView Rating Details
11/15/2017HC WainwrightReiterated RatingBuy$24.00N/AView Rating Details
11/2/2017Royal Bank of CanadaReiterated RatingHold$17.00N/AView Rating Details
6/30/2017AegisReiterated RatingBuyHighView Rating Details
5/17/2017Needham & Company LLCReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
4/26/2017JMP SecuritiesBoost Price TargetOutperform$19.00 -> $21.00HighView Rating Details
9/29/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingHold$8.00N/AView Rating Details
5/8/2016Morgan StanleyReiterated RatingBuyN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$24.00 -> $16.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Akebia Therapeutics (NASDAQ:AKBA) Earnings History and Estimates Chart

Earnings by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ AKBA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.36)N/AView Earnings Details
11/8/2017Q3 2017($0.56)($0.49)$34.00 million$41.28 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.53)$26.50 million$28.52 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.15)($1.15)$16.50 million$20.87 millionViewN/AView Earnings Details
3/6/2017Q4 2016$0.77($0.99)$125.00 million$1.54 millionViewListenView Earnings Details
11/9/2016Q3($1.09)($0.96)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.57)($0.95)$6.00 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.43)($0.70)$9.00 millionViewN/AView Earnings Details
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.57)($0.53)ViewN/AView Earnings Details
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.34)($0.39)ViewN/AView Earnings Details
5/12/2014Q1 2014($43.37)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Akebia Therapeutics (NASDAQ:AKBA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.25 EPS
Next Year EPS Consensus Estimate: $-0.87 EPS

Dividends

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Akebia Therapeutics (NASDAQ AKBA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.95%
Institutional Ownership Percentage: 66.99%
Insider Trades by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Insider Trades by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ AKBA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Duane NashDirectorSell1,000$14.62$14,620.00View SEC Filing  
10/2/2017Duane NashDirectorSell1,188$19.64$23,332.32View SEC Filing  
10/2/2017Michel DahanSVPSell1,398$19.64$27,456.72View SEC Filing  
9/28/2017Michel DahanSVPSell5,000$19.30$96,500.0097,224View SEC Filing  
8/15/2017Michel DahanSVPSell5,000$15.00$75,000.00102,224View SEC Filing  
7/5/2017Muneer A SatterDirectorBuy1,034,482$14.50$14,999,989.00View SEC Filing  
7/3/2017Duane NashDirectorSell990$14.27$14,127.3023,687View SEC Filing  
7/3/2017Nicole R. HadasSVPSell1,554$14.26$22,160.04View SEC Filing  
4/3/2017Duane NashDirectorSell991$9.20$9,117.2024,677View SEC Filing  
4/3/2017Nicole R HadasSVPSell1,556$9.18$14,284.08109,856View SEC Filing  
1/3/2017Duane NashDirectorSell1,980$10.46$20,710.8025,668View SEC Filing  
1/1/2017Nicole R. HadasSVPSell1,810$10.49$18,986.90View SEC Filing  
7/6/2016Duane NashDirectorSell1,980$7.48$14,810.4029,629View SEC Filing  
7/5/2016Nicole R. HadasSVPSell1,557$7.47$11,630.79View SEC Filing  
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.4174,956View SEC Filing  
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.2865,260View SEC Filing  
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akebia Therapeutics (NASDAQ AKBA) News Headlines

Source:
DateHeadline
Akebia Therapeutics Inc (AKBA) Receives Consensus Recommendation of "Buy" from AnalystsAkebia Therapeutics Inc (AKBA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 20 at 10:46 AM
Akebia Therapeutics Inc (AKBA) Director Sells $14,620.00 in StockAkebia Therapeutics Inc (AKBA) Director Sells $14,620.00 in Stock
www.americanbankingnews.com - February 16 at 10:38 PM
Zymeworks (ZYME) and Akebia Therapeutics (AKBA) Head-To-Head AnalysisZymeworks (ZYME) and Akebia Therapeutics (AKBA) Head-To-Head Analysis
www.americanbankingnews.com - February 14 at 7:18 PM
Akebia Therapeutics (AKBA) Receives "Buy" Rating from MizuhoAkebia Therapeutics (AKBA) Receives "Buy" Rating from Mizuho
www.americanbankingnews.com - February 13 at 12:24 PM
Akebia Therapeutics (AKBA) Provides Update on VadadustatAkebia Therapeutics (AKBA) Provides Update on Vadadustat
www.streetinsider.com - February 12 at 9:34 AM
Akebia Therapeutics Provides Update on Vadadustat Development ProgramAkebia Therapeutics Provides Update on Vadadustat Development Program
finance.yahoo.com - February 12 at 9:34 AM
Akebia Therapeutics to Present at Upcoming February Investor ConferencesAkebia Therapeutics to Present at Upcoming February Investor Conferences
finance.yahoo.com - February 8 at 8:31 AM
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release)
www.businesswire.com - February 3 at 4:06 PM
Investors Purchase High Volume of Call Options on Akebia Therapeutics (AKBA)Investors Purchase High Volume of Call Options on Akebia Therapeutics (AKBA)
www.americanbankingnews.com - January 26 at 1:40 AM
Akebia Therapeutics (AKBA) Announces Positive Top-Line Results ... - StreetInsider.comAkebia Therapeutics (AKBA) Announces Positive Top-Line Results ... - StreetInsider.com
www.streetinsider.com - January 5 at 3:30 PM
Akebia Therapeutics (AKBA) Stock Rating Lowered by Zacks Investment ResearchAkebia Therapeutics (AKBA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 2 at 6:46 PM
Akebia Therapeutics Inc (AKBA) Given Average Recommendation of "Buy" by AnalystsAkebia Therapeutics Inc (AKBA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 1 at 8:02 AM
Akebia Therapeutics (AKBA) Now Covered by Piper Jaffray CompaniesAkebia Therapeutics (AKBA) Now Covered by Piper Jaffray Companies
www.americanbankingnews.com - December 18 at 5:35 PM
Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You? - NasdaqMarket Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You? - Nasdaq
www.nasdaq.com - December 15 at 3:32 PM
Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?
finance.yahoo.com - December 13 at 9:29 AM
BTIG Research Begins Coverage on Akebia Therapeutics (AKBA)BTIG Research Begins Coverage on Akebia Therapeutics (AKBA)
www.americanbankingnews.com - December 7 at 6:26 PM
BTIG Starts Akebia Therapeutics (AKBA) at Buy - StreetInsider.comBTIG Starts Akebia Therapeutics (AKBA) at Buy - StreetInsider.com
www.streetinsider.com - December 7 at 3:32 PM
Akebia Therapeutics, Inc. (AKBA) Receives Average Rating of "Buy" from AnalystsAkebia Therapeutics, Inc. (AKBA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 7 at 7:56 AM
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimeticsThe Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
finance.yahoo.com - December 6 at 9:46 AM
5 Top-Ranked Drug Stocks that are Broker Favorites5 Top-Ranked Drug Stocks that are Broker Favorites
finance.yahoo.com - December 5 at 9:37 AM
Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in SessionConcert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session
finance.yahoo.com - December 4 at 9:28 AM
Akebia Therapeutics (AKBA) Downgraded by ValuEngineAkebia Therapeutics (AKBA) Downgraded by ValuEngine
www.americanbankingnews.com - December 4 at 12:22 AM
Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Akebia Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - December 2 at 11:08 AM
GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%
www.zacks.com - November 28 at 8:21 AM
Akebia Therapeutics, Inc. (AKBA) Stock Rating Reaffirmed by HC WainwrightAkebia Therapeutics, Inc. (AKBA) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 19 at 6:20 PM
Critical Review: Akebia Therapeutics (AKBA) & Its CompetitorsCritical Review: Akebia Therapeutics (AKBA) & Its Competitors
www.americanbankingnews.com - November 19 at 5:06 PM
Akebia Therapeutics to Participate in Upcoming Investor ConferencesAkebia Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 16 at 10:57 AM
Akebia Therapeutics, Inc. (AKBA) Lifted to Buy at Zacks Investment ResearchAkebia Therapeutics, Inc. (AKBA) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 13 at 8:30 PM
Akebia Therapeutics, Inc. (AKBA) Given Average Recommendation of "Buy" by BrokeragesAkebia Therapeutics, Inc. (AKBA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 12 at 10:20 AM
Akebia Therapeutics Enters Oversold Territory (AKBA)Akebia Therapeutics Enters Oversold Territory (AKBA)
www.thestreet.com - November 9 at 4:41 PM
Akebia Therapeutics, Inc. (AKBA) Releases Quarterly  Earnings Results, Beats Estimates By $0.07 EPSAkebia Therapeutics, Inc. (AKBA) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - November 9 at 2:27 PM
Akebia Therapeutics Announces Third Quarter 2017 Financial ... - Business Wire (press release)Akebia Therapeutics Announces Third Quarter 2017 Financial ... - Business Wire (press release)
www.businesswire.com - November 9 at 4:04 AM
Akebia Therapeutics Announces Third Quarter 2017 Financial ResultsAkebia Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 5:56 PM
Akebia Therapeutics reports 3Q lossAkebia Therapeutics reports 3Q loss
finance.yahoo.com - November 8 at 5:56 PM
Is Akebia Therapeutics Inc’s (AKBA) Liquidity As Good As Its Solvency?Is Akebia Therapeutics Inc’s (AKBA) Liquidity As Good As Its Solvency?
finance.yahoo.com - November 7 at 5:15 PM
Royal Bank Of Canada Reiterates Hold Rating for Akebia Therapeutics, Inc. (AKBA)Royal Bank Of Canada Reiterates Hold Rating for Akebia Therapeutics, Inc. (AKBA)
www.americanbankingnews.com - November 2 at 3:20 PM
Akebia Therapeutics, Inc. (AKBA) Scheduled to Post Quarterly Earnings on TuesdayAkebia Therapeutics, Inc. (AKBA) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 7:44 AM
Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : October 27, 2017Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : October 27, 2017
finance.yahoo.com - October 27 at 5:48 PM
Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : October 26, 2017Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : October 26, 2017
finance.yahoo.com - October 26 at 11:08 AM
Biotech Stock Performance Review -- Agenus, Akebia Therapeutics ... - PR Newswire (press release)Biotech Stock Performance Review -- Agenus, Akebia Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - October 20 at 10:37 PM
Akebia Therapeutics, Inc. (AKBA) Given Average Rating of "Buy" by AnalystsAkebia Therapeutics, Inc. (AKBA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 18 at 10:30 AM
Acer Therapeutics Welcomes Two New Members to its Board of DirectorsAcer Therapeutics Welcomes Two New Members to its Board of Directors
feeds.benzinga.com - October 12 at 9:25 AM
Akebia Therapeutics, Inc. (AKBA) Downgraded by Zacks Investment Research to HoldAkebia Therapeutics, Inc. (AKBA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 10 at 8:56 PM
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - October 5 at 1:09 PM
Akebia Therapeutics, Inc. (AKBA) Director Duane Nash Sells 1,188 SharesAkebia Therapeutics, Inc. (AKBA) Director Duane Nash Sells 1,188 Shares
www.americanbankingnews.com - October 4 at 9:08 PM
Michel Dahan Sells 1,398 Shares of Akebia Therapeutics, Inc. (AKBA) StockMichel Dahan Sells 1,398 Shares of Akebia Therapeutics, Inc. (AKBA) Stock
www.americanbankingnews.com - October 4 at 8:48 PM
Akebia Therapeutics, Inc. (AKBA) Earns Buy Rating from Analysts at MizuhoAkebia Therapeutics, Inc. (AKBA) Earns Buy Rating from Analysts at Mizuho
www.americanbankingnews.com - October 4 at 5:26 PM
Akebia Therapeutics, Inc. (AKBA) SVP Sells $96,500.00 in StockAkebia Therapeutics, Inc. (AKBA) SVP Sells $96,500.00 in Stock
www.americanbankingnews.com - October 2 at 7:42 PM
AKBA Crosses Above Average Analyst TargetAKBA Crosses Above Average Analyst Target
www.thestreet.com - October 2 at 3:30 PM
Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney DiseaseAkebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease
www.businesswire.com - September 27 at 8:11 PM

SEC Filings

Akebia Therapeutics (NASDAQ:AKBA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akebia Therapeutics (NASDAQ:AKBA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akebia Therapeutics (NASDAQ AKBA) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.